Medtronic PLC and Novo Nordisk A/S will collaborate to integrate data points from their respective digital devices to help diabetic patients manage their glucose intake more efficiently.
Under the agreement, data from Novo Nordisk's smart insulin pens will be merged into data obtained from Medtronic's continuous glucose monitoring, or CGM, devices.
"Our new agreement with Novo Nordisk will streamline the sharing of two of the most important pieces of information — glucose measurements and insulin dosed," Alejandro Galindo, president of the Advanced Insulin Management division within the Diabetes Group at Medtronic, said in a news release.
The CGM devices, like Medtronic's Guardian connect systems, feature predictive alerts that allow patients to be mindful of upcoming high and low glucose events. By integrating data from smart insulin pens into such devices, diabetic patients can significantly improve daily medication management, the companies said in a statement.
